3,4-Ethylenedioxyamphetamine

EDA
Clinical data
Other names3,4-Ethylenedioxyamphetamine; EDA; EDA-6; α-Methyl-1,4-benzodioxan-6-ethylamine
Identifiers
  • 1-(2,3-dihydro-1,4-benzodioxin-6-yl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC11H15NO2
Molar mass193.246 g·mol−1
3D model (JSmol)
  • CC(CC1=CC2=C(C=C1)OCCO2)N
  • InChI=1S/C11H15NO2/c1-8(12)6-9-2-3-10-11(7-9)14-5-4-13-10/h2-3,7-8H,4-6,12H2,1H3
  • Key:HDECLNXLHDXDKE-UHFFFAOYSA-N

3,4-Ethylenedioxyamphetamine (EDA), also known as EDA-6, is a drug of the amphetamine family related to 3,4-methylenedioxyamphetamine (MDA). It is closely related to analogues including 3,4-ethylenedioxymethamphetamine (EDMA), 3,4-ethylidenedioxyamphetamine (EIDA), and 3,4-isopropylidenedioxyamphetamine (IDA). EDMA, the N-methylated analogue of EDA, is known to be a serotonin–norepinephrine–dopamine releasing agent (SNDRA). According to Alexander Shulgin however, the drug only produced limited psychoactive effects in humans at doses in the range of 150 to 250 mg.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.